2-{1-[2-(3,4-dihydroquinolin-1(2H)-yl)-2-oxoethyl]-1H-indol-3-yl}-N,N-diethyl-2-oxoacetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-{1-[2-(3,4-dihydroquinolin-1(2H)-yl)-2-oxoethyl]-1H-indol-3-yl}-N,N-diethyl-2-oxoacetamide
• 英文别名: 2-[1-[2-(3,4-dihydro-2H-quinolin-1-yl)-2-oxoethyl]indol-3-yl]-N,N-diethyl-2-oxoacetamide
• 化学式: C₂₅H₂₇N₃O₃
• 分子量: 417.5
• InChiKey: XNTNWXJPFGTWBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  62.6
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors
  申请人：Texas Tech University System

  公开号：US10463649B2

  公开（公告）日：2019-11-05

  The present invention includes compositions and methods for inhibiting MCL-1, including novel inhibitors of MCL-1, and compositions and methods for treating a subject with cancer that is refractory to one or more MAPK pathway protein inhibitors.

  本发明包括抑制MCL-1的组合物和方法，包括MCL-1的新型抑制剂，以及治疗对一种或多种MAPK通路蛋白抑制剂难治的癌症患者的组合物和方法。
• Inhibitors of Mcl-1 as Drugs to Overcome Resistance to BRAF Inhibitors and MEK Inhibitors
  申请人：Texas Tech University System

  公开号：US20180161313A1

  公开（公告）日：2018-06-14

  The present invention includes compositions and methods for inhibiting MCL-1, including novel inhibitors of MCL-1, and compositions and methods for treating a subject with cancer that is refractory to one or more MAPK pathway protein inhibitors.